Insomnia Management in Chronic Kidney Disease

General Principles

The KDIGO guidelines emphasize that people with CKD are more susceptible to nephrotoxic and adverse effects of medications, requiring careful benefit-harm assessment 1.
When prescribing medications to CKD patients, validated eGFR equations using serum creatinine are appropriate for most drug dosing decisions 1.
For medications with narrow therapeutic windows or significant toxicity risk, more precise GFR assessment may be warranted 1.

Ramelteon 8mg has no dependence potential, is not DEA-scheduled, and represents a safer option for CKD patients with insomnia, particularly those with substance use history 5.
Low-dose doxepin 3-6mg is highly effective for sleep maintenance with minimal anticholinergic effects at these doses and favorable safety in elderly/compromised patients 5.
Benzodiazepines should be avoided as first-line treatment due to accumulation risk, falls, cognitive impairment, and respiratory depression 5.
Zolpidem requires dose reduction (5mg) in vulnerable populations and carries FDA warnings about complex sleep behaviors 5.

Monitor eGFR, electrolytes, and therapeutic medication levels when indicated, particularly for medications with narrow therapeutic windows 1.
Perform thorough medication review periodically and at transitions of care to assess adherence, continued indication, and potential drug interactions 1.
Screen for complex sleep behaviors (sleep-driving, sleep-walking) and discontinue immediately if observed 5.
Assess for excessive daytime sedation, fall risk, and cognitive impairment, which are heightened in CKD patients 1, 4.

Cognitive Behavioral Therapy for Insomnia (CBT-I) should be initiated before or alongside pharmacotherapy 7, 5.
For sleep onset, Ramelteon 8mg is recommended as the safest option in CKD, with no renal dose adjustment needed 5, 6.
For sleep maintenance, low-dose doxepin 3-6mg is recommended due to minimal side effects and favorable safety in compromised patients 5, 4.
If lemborexant is chosen, start at standard 5mg dose, can increase to 10mg if tolerated, with close monitoring for sedation and falls 5.

Over-the-counter antihistamines (diphenhydramine) should be avoided in CKD due to anticholinergic burden, urinary retention risk, and lack of efficacy data 5, 6.
Trazodone lacks evidence for insomnia and has an unfavorable side effect profile 5, 4.
Atypical antipsychotics (quetiapine, olanzapine) carry significant metabolic risks and lack evidence for primary insomnia 5, 4.
Long-acting benzodiazepines accumulate in CKD and increase fall/fracture risk 5, 6.